92 related articles for article (PubMed ID: 31907737)
1. Patient selection for a developmental therapeutics program using whole genome and Transcriptome analysis.
Lavoie JM; Mitchell T; Lee SE; Deol B; Chia SK; Gelmon KA; Kollmannsberger CK; Tinker AV; Jones SJM; Marra M; Laskin J; Renouf DJ
Invest New Drugs; 2020 Oct; 38(5):1601-1604. PubMed ID: 31907737
[TBL] [Abstract][Full Text] [Related]
2. Whole-genome and transcriptome analysis enhances precision cancer treatment options.
Pleasance E; Bohm A; Williamson LM; Nelson JMT; Shen Y; Bonakdar M; Titmuss E; Csizmok V; Wee K; Hosseinzadeh S; Grisdale CJ; Reisle C; Taylor GA; Lewis E; Jones MR; Bleile D; Sadeghi S; Zhang W; Davies A; Pellegrini B; Wong T; Bowlby R; Chan SK; Mungall KL; Chuah E; Mungall AJ; Moore RA; Zhao Y; Deol B; Fisic A; Fok A; Regier DA; Weymann D; Schaeffer DF; Young S; Yip S; Schrader K; Levasseur N; Taylor SK; Feng X; Tinker A; Savage KJ; Chia S; Gelmon K; Sun S; Lim H; Renouf DJ; Jones SJM; Marra MA; Laskin J
Ann Oncol; 2022 Sep; 33(9):939-949. PubMed ID: 35691590
[TBL] [Abstract][Full Text] [Related]
3. The impact of whole genome and transcriptome analysis (WGTA) on predictive biomarker discovery and diagnostic accuracy of advanced malignancies.
Tessier-Cloutier B; Grewal JK; Jones MR; Pleasance E; Shen Y; Cai E; Dunham C; Hoang L; Horst B; Huntsman DG; Ionescu D; Karnezis AN; Lee AF; Lee CH; Lee TH; Twa DD; Mungall AJ; Mungall K; Naso JR; Ng T; Schaeffer DF; Sheffield BS; Skinnider B; Smith T; Williamson L; Zhong E; Regier DA; Laskin J; Marra MA; Gilks CB; Jones SJ; Yip S
J Pathol Clin Res; 2022 Jul; 8(4):395-407. PubMed ID: 35257510
[TBL] [Abstract][Full Text] [Related]
4. Matching methods in precision oncology: An introduction and illustrative example.
Weymann D; Laskin J; Jones SJM; Lim H; Renouf DJ; Roscoe R; Schrader KA; Sun S; Yip S; Marra MA; Regier DA
Mol Genet Genomic Med; 2021 Jan; 9(1):e1554. PubMed ID: 33237632
[TBL] [Abstract][Full Text] [Related]
5. Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.
Le Tourneau C; Delord JP; Gonçalves A; Gavoille C; Dubot C; Isambert N; Campone M; Trédan O; Massiani MA; Mauborgne C; Armanet S; Servant N; Bièche I; Bernard V; Gentien D; Jezequel P; Attignon V; Boyault S; Vincent-Salomon A; Servois V; Sablin MP; Kamal M; Paoletti X;
Lancet Oncol; 2015 Oct; 16(13):1324-34. PubMed ID: 26342236
[TBL] [Abstract][Full Text] [Related]
6. Long-term overall survival and prognostic score predicting survival: the IMPACT study in precision medicine.
Tsimberidou AM; Hong DS; Wheler JJ; Falchook GS; Janku F; Naing A; Fu S; Piha-Paul S; Cartwright C; Broaddus RR; Nogueras Gonzalez GM; Hwu P; Kurzrock R
J Hematol Oncol; 2019 Dec; 12(1):145. PubMed ID: 31888672
[TBL] [Abstract][Full Text] [Related]
7. Copenhagen Prospective Personalized Oncology (CoPPO)-Clinical Utility of Using Molecular Profiling to Select Patients to Phase I Trials.
Tuxen IV; Rohrberg KS; Oestrup O; Ahlborn LB; Schmidt AY; Spanggaard I; Hasselby JP; Santoni-Rugiu E; Yde CW; Mau-Sørensen M; Nielsen FC; Lassen U
Clin Cancer Res; 2019 Feb; 25(4):1239-1247. PubMed ID: 30274980
[TBL] [Abstract][Full Text] [Related]
8. Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial.
Stockley TL; Oza AM; Berman HK; Leighl NB; Knox JJ; Shepherd FA; Chen EX; Krzyzanowska MK; Dhani N; Joshua AM; Tsao MS; Serra S; Clarke B; Roehrl MH; Zhang T; Sukhai MA; Califaretti N; Trinkaus M; Shaw P; van der Kwast T; Wang L; Virtanen C; Kim RH; Razak AR; Hansen AR; Yu C; Pugh TJ; Kamel-Reid S; Siu LL; Bedard PL
Genome Med; 2016 Oct; 8(1):109. PubMed ID: 27782854
[TBL] [Abstract][Full Text] [Related]
9. A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.
Sun R; Limkin EJ; Vakalopoulou M; Dercle L; Champiat S; Han SR; Verlingue L; Brandao D; Lancia A; Ammari S; Hollebecque A; Scoazec JY; Marabelle A; Massard C; Soria JC; Robert C; Paragios N; Deutsch E; Ferté C
Lancet Oncol; 2018 Sep; 19(9):1180-1191. PubMed ID: 30120041
[TBL] [Abstract][Full Text] [Related]
10. Whole genome and transcriptome integrated analyses guide clinical care of pediatric poor prognosis cancers.
Deyell RJ; Shen Y; Titmuss E; Dixon K; Williamson LM; Pleasance E; Nelson JMT; Abbasi S; Krzywinski M; Armstrong L; Bonakdar M; Ch'ng C; Chuah E; Dunham C; Fok A; Jones M; Lee AF; Ma Y; Moore RA; Mungall AJ; Mungall KL; Rogers PC; Schrader KA; Virani A; Wee K; Young SS; Zhao Y; Jones SJM; Laskin J; Marra MA; Rassekh SR
Nat Commun; 2024 May; 15(1):4165. PubMed ID: 38755180
[TBL] [Abstract][Full Text] [Related]
11. Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme.
Varnier R; Le Saux O; Chabaud S; Garin G; Sohier E; Wang Q; Paindavoine S; Pérol D; Baudet C; Attignon V; Pissaloux D; Heudel P; You B; Leyronnas C; Collard O; Trédan O; Bonnin N; Long J; Jacquin JP; Cassier PA; Derbel O; Freyer G; Viari A; Blay JY; Ray-Coquard I
Eur J Cancer; 2019 Sep; 118():156-165. PubMed ID: 31351267
[TBL] [Abstract][Full Text] [Related]
12. Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
Beltran H; Eng K; Mosquera JM; Sigaras A; Romanel A; Rennert H; Kossai M; Pauli C; Faltas B; Fontugne J; Park K; Banfelder J; Prandi D; Madhukar N; Zhang T; Padilla J; Greco N; McNary TJ; Herrscher E; Wilkes D; MacDonald TY; Xue H; Vacic V; Emde AK; Oschwald D; Tan AY; Chen Z; Collins C; Gleave ME; Wang Y; Chakravarty D; Schiffman M; Kim R; Campagne F; Robinson BD; Nanus DM; Tagawa ST; Xiang JZ; Smogorzewska A; Demichelis F; Rickman DS; Sboner A; Elemento O; Rubin MA
JAMA Oncol; 2015 Jul; 1(4):466-74. PubMed ID: 26181256
[TBL] [Abstract][Full Text] [Related]
13. Early-stage economic analysis of research-based comprehensive genomic sequencing for advanced cancer care.
Weymann D; Laskin J; Jones SJM; Roscoe R; Lim HJ; Renouf DJ; Schrader KA; Sun S; Yip S; Marra MA; Regier DA
J Community Genet; 2022 Oct; 13(5):523-538. PubMed ID: 34843087
[TBL] [Abstract][Full Text] [Related]
14. Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center Study.
Wheler JJ; Janku F; Naing A; Li Y; Stephen B; Zinner R; Subbiah V; Fu S; Karp D; Falchook GS; Tsimberidou AM; Piha-Paul S; Anderson R; Ke D; Miller V; Yelensky R; Lee JJ; Hong DS; Kurzrock R
Cancer Res; 2016 Jul; 76(13):3690-701. PubMed ID: 27197177
[TBL] [Abstract][Full Text] [Related]
15. Limited evolution of the actionable metastatic cancer genome under therapeutic pressure.
van de Haar J; Hoes LR; Roepman P; Lolkema MP; Verheul HMW; Gelderblom H; de Langen AJ; Smit EF; Cuppen E; Wessels LFA; Voest EE
Nat Med; 2021 Sep; 27(9):1553-1563. PubMed ID: 34373653
[TBL] [Abstract][Full Text] [Related]
16. Clinical genomic profiling to identify actionable alterations for investigational therapies in patients with diverse sarcomas.
Groisberg R; Hong DS; Holla V; Janku F; Piha-Paul S; Ravi V; Benjamin R; Kumar Patel S; Somaiah N; Conley A; Ali SM; Schrock AB; Ross JS; Stephens PJ; Miller VA; Sen S; Herzog C; Meric-Bernstam F; Subbiah V
Oncotarget; 2017 Jun; 8(24):39254-39267. PubMed ID: 28424409
[TBL] [Abstract][Full Text] [Related]
17. Precision oncology using a clinician-directed, tailored approach to molecular profiling.
Lam M; Tran B; Beck S; Tie J; Herath D; Whittle J; Kwan EM; Fox SB; Fellowes A; Ananda S; Lipton L; Gibbs P; Rosenthal MA; Desai J
Asia Pac J Clin Oncol; 2018 Feb; 14(1):84-90. PubMed ID: 29083093
[TBL] [Abstract][Full Text] [Related]
18. Personalised selection of experimental treatment in patients with advanced solid cancer is feasible using whole-genome sequencing.
Pruis MA; Groenendijk FH; Badloe KS; van Puffelen A; Robbrecht D; Dinjens WNM; Sleijfer S; Dingemans AC; von der Thüsen JH; Roepman P; Lolkema MP
Br J Cancer; 2022 Sep; 127(4):776-783. PubMed ID: 35606463
[TBL] [Abstract][Full Text] [Related]
19. Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening Era.
Tan T; Rheaume M; Wang L; Chow H; Spreafico A; Hansen AR; Razak ARA; Siu LL; Bedard PL
Oncologist; 2019 Jul; 24(7):e518-e525. PubMed ID: 30833487
[TBL] [Abstract][Full Text] [Related]
20. Feasibility of Large-Scale Genomic Testing to Facilitate Enrollment Onto Genomically Matched Clinical Trials.
Meric-Bernstam F; Brusco L; Shaw K; Horombe C; Kopetz S; Davies MA; Routbort M; Piha-Paul SA; Janku F; Ueno N; Hong D; De Groot J; Ravi V; Li Y; Luthra R; Patel K; Broaddus R; Mendelsohn J; Mills GB
J Clin Oncol; 2015 Sep; 33(25):2753-62. PubMed ID: 26014291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
